• +86-0635-6175299
  • li_ye@inyelchem.com
  • Company Details

 Shandong Haohong Biotechnology Co., Ltd.

HomeNewsCoronavirus (COVID-19) Update: July 30, 2021

Coronavirus (COVID-19) Update: July 30, 2021

2021-08-03
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

Today, the FDA revised the Emergency Use Authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) to add an authorization of REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms) who are at high risk for progression to severe COVID-19, including hospitalization or death. REGEN-COV is not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus -- only after exposure to the virus. REGEN-COV should only be used as post-exposure prophylaxis for specific patient populations. Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19. FDA has authorized three vaccines to prevent COVID-19 and serious clinical outcomes caused by COVID-19, including hospitalization and death. FDA urges you to get vaccinated, if you are eligible. Learn more about FDA`s COVID-19 vaccination efforts.


On Wednesday, July 28, the FDA revised the EUA for baricitinib (sold under the brand name Olumiant) now authorizing baricitinib alone for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Under the revised EUA, baricitinib is no longer required to be administered with remdesivir (Veklury). Baricitinib is not FDA-approved as a treatment for COVID-19.
On Wednesday, the FDA authorized an extension for the shelf life of the refrigerated Janssen (Johnson & Johnson) COVID-19 Vaccine, allowing the product to be stored at 2-8 degrees Celsius for six months. This extension from four and a half months to six months was granted following a thorough review of data submitted by Janssen and applies to all refrigerated vials of Janssen COVID-19 Vaccine that have been held in accordance with the manufacturer`s storage conditions.

The expiration dates for vaccines that are authorized under an EUA may be extended based on data submitted by the manufacturers, and in accordance with FDA`s authorization. Health care providers administering the vaccine should check the company`s website, www.vaxcheck.jnjExternal Link Disclaimer, to obtain the most up-to-date expiration dates for specific lots of the Janssen COVID-19 vaccine.

HomeNewsCoronavirus (COVID-19) Update: July 30, 2021

Home

Product

Whatsapp

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send